Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

OncoAlert round up July 28th to August 3rd, 2023

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database